It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
This study aims to perform a comprehensive genomic analysis to assess the influence of overexpression of MYO1E in non-small cell lung carcinoma (NSCLC) and whether there are differences in survival and mortality risk in NSCLC patients depending on both DNA methylation and RNA expression of MYO1E. The DNA methylation probe cg13887966 was inversely correlated with MYO1E RNA expression in both LUAD and LUSC subpopulations showing that lower MYO1E RNA expression was associated with higher MYO1E DNA methylation. Late stages of lung cancer showed significantly lower MYO1E DNA methylation and significantly higher MYO1E RNA expression for LUAD but not for LUSC. Low DNA methylation as well as high RNA expression of MYO1E are associated with a shorter median survival time and an increased risk of mortality for LUAD, but not for LUSC. This study suggests that changes in MYO1E methylation and expression in LUAD patients may have an essential role in lung cancer’s pathogenesis. It shows the utility of MYO1E DNA methylation and RNA expression in predicting survival for LUAD patients. Also, given the low normal expression of MYO1E in blood cells MYO1E DNA methylation has the potential to be used as circulating tumor marker in liquid biopsies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Mayo Clinic, Department of Neurological Surgery, Rochester, USA (GRID:grid.66875.3a) (ISNI:0000 0004 0459 167X)
2 University of Illinois at Chicago College of Medicine, Department of Surgery, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
3 University of Illinois at Chicago, Cancer Center, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
4 University of Illinois at Chicago College of Medicine, Division of Hematology Oncology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
5 University of Illinois at Chicago College of Medicine, Department of Pathology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
6 University of Illinois at Chicago College of Medicine, Department of Radiology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
7 University of Patras, Molecular Oncology Laboratory, Division of Oncology, Medical School, Patras, Greece (GRID:grid.11047.33) (ISNI:0000 0004 0576 5395)
8 University of Illinois at Chicago College of Medicine, Division of Cardiothoracic Surgery, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
9 Jesse Brown VA Medical Center, Medical and Research Services, Chicago, USA (GRID:grid.280892.9) (ISNI:0000 0004 0419 4711); University of Illinois at Chicago College of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy Medicine, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
10 University of Illinois at Chicago College of Medicine, Division of Hematology Oncology, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Jesse Brown VA Medical Center, Medical and Research Services, Chicago, USA (GRID:grid.280892.9) (ISNI:0000 0004 0419 4711)
11 University of Illinois at Chicago College of Medicine, Department of Surgery, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Louisiana State University, Section of Surgical Oncology, Department of Surgery, New Orleans, USA (GRID:grid.64337.35) (ISNI:0000 0001 0662 7451)
12 University of Illinois at Chicago, Cancer Center, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); University of Illinois at Chicago College of Medicine, Division of Cardiothoracic Surgery, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)
13 Johns Hopkins University School of Medicine, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA (GRID:grid.21107.35) (ISNI:0000 0001 2171 9311); Vavilov Institute of General Genetics, Russian Academy of Sciences, Laboratory of Systems Biology and Computational Genetics, Moscow, Russia (GRID:grid.433823.d) (ISNI:0000 0004 0404 8765)
14 University of Illinois at Chicago, Cancer Center, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319); Jesse Brown VA Medical Center, Medical and Research Services, Chicago, USA (GRID:grid.280892.9) (ISNI:0000 0004 0419 4711); University of Illinois College of Medicine, Department of Surgery, Chicago, USA (GRID:grid.185648.6) (ISNI:0000 0001 2175 0319)